QR code

Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer

Abstract First-line treatment options for patients with metastatic hormone-sensitive prostate cancer (HSPC) are divided into two groups: androgen receptor signaling inhibitor (ARSI)-based doublet therapy and triplet therapy (which includes chemotherapy in addition to doublet therapy). However, diffe...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Keita Hayakawa, Takashi Ueda, Masahiro Iehara, Yusuke Gabata, Junki Murashita, Hikaru Takahashi, Yumiko Saito, Masatsugu Miyashita, Yasuhiro Yamada, Takumi Shiraishi, Atsuko Fujihara, Masayoshi Okumi, Fumiya Hongo, Osamu Ukimura
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Portfolio 2026-03-01
Reeks:Scientific Reports
Onderwerpen:
Docetaxel
Darolutamide
Abiraterone acetate
Apalutamide
Enzalutamide
Metastatic hormone-sensitive prostate cancer
Online toegang:https://doi.org/10.1038/s41598-026-44627-w
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items